What is Juniper Biomedical?
Juniper Biomedical is at the forefront of medical technology, developing a precision neuromodulation platform designed to offer patients less invasive, safer, and more effective therapeutic options. The company's unique capabilities aim to revolutionize treatment for various neurological conditions, positioning it as a key player in the burgeoning field of neurotherapeutics. The substantial backing indicates strong market confidence in their technological advancements and therapeutic potential.
How much funding has Juniper Biomedical raised?
Juniper Biomedical has raised a total of $3M across 2 funding rounds:
Grant
$1M
Angel/Seed
$2M
Grant (2024): $1M with participation from NIH SPARC Neuromod Prize
Angel/Seed (2024): $2M led by Hub Angel Investment Group Fund V and ATMA Capital
Key Investors in Juniper Biomedical
Hub Angel Investment Group Fund V
Hub Angel Investment Group is a prominent angel investment group based in Boston, specializing in funding young tech and life science companies in the Northeastern United States since 2000. They aim to support entrepreneurs of all backgrounds and provide value beyond financial investment through connections and advice.
ATMA Capital
Atma Capital focuses on making control investments into new businesses, crafting strategic forward plans, and executing operating initiatives to help companies succeed. They are committed front-line professionals dedicated to long-term business success.
NIH SPARC Neuromod Prize
Undisclosed investor participating in the funding round.
What's next for Juniper Biomedical?
With this major strategic investment, Juniper Biomedical is poised for significant expansion and further development of its precision neuromodulation technology. The enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially preparing for broader market penetration. This capital infusion will likely accelerate the company's trajectory towards bringing its innovative patient therapies to a wider audience, reinforcing its commitment to improving healthcare outcomes through advanced technological solutions.
See full Juniper Biomedical company page
